• C H Clark, E A Miles, M T Guerrero Urbano, S A Bhide, A M Bidmead, K J Harrington, C M Nutting, and UK PARSPORT Trial Management Group collaborators.
• Department of Physics, Royal Marsden NHS Foundation Trust, London and Sutton, Surrey, UK. catharine.clark@rmh.nhs.uk
• Br J Radiol. 2009 Jul 1; 82 (979): 585-94.

AbstractThe purpose of this study was to compare conventional radiotherapy with parotid gland-sparing intensity-modulated radiation therapy (IMRT) using the PARSPORT trial. The validity of such a trial depends on the radiotherapy planning and delivery meeting a defined standard across all centres. At the outset, many of the centres had little or no experience of delivering IMRT; therefore, quality assurance processes were devised to ensure consistency and standardisation of all processes for comparison within the trial. The pre-trial quality assurance (QA) programme and results are described. Each centre undertook exercises in target volume definition and treatment planning, completed a resource questionnaire and produced a process document. Additionally, the QA team visited each participating centre. Each exercise had to be accepted before patients could be recruited into the trial. 10 centres successfully completed the quality assurance exercises. A range of treatment planning systems, linear accelerators and delivery methods were used for the planning exercises, and all the plans created reached the standard required for participation in this multicentre trial. All 10 participating centres achieved implementation of a comprehensive and robust IMRT programme for treatment of head and neck cancer.

17 keywords...

hide…